$277 Million is the total value of Stonepine Capital Management, LLC's 21 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 59.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | QUIDELORTHO CORP | $51,325,638 | +106.4% | 619,426 | +122.0% | 18.51% | +122.0% | |
| EOLS | Buy | EVOLUS INC | $32,760,052 | +569.0% | 4,506,197 | +678.5% | 11.82% | +619.7% |
| ADMA | Buy | ADMA BIOLOGICS INC | $32,447,354 | +27.9% | 8,793,321 | +14.8% | 11.70% | +37.6% |
| GLPG | Sell | GALAPAGOS NV-SPON ADRspon adr | $27,757,118 | -8.2% | 682,664 | -12.7% | 10.01% | -1.2% |
| New | AMYLYX PHARMACEUTICALS INC | $24,180,574 | – | 1,121,028 | +100.0% | 8.72% | – | |
| Buy | MAXCYTE INC | $18,208,144 | +35.9% | 3,966,916 | +46.5% | 6.57% | +46.2% | |
| Sell | XERIS BIOPHARMA HOLDINGS INC | $14,410,597 | +2.3% | 5,500,228 | -36.3% | 5.20% | +10.1% | |
| Sell | THIRD HARMONIC BIO INC | $13,435,047 | +4.1% | 2,793,149 | -10.8% | 4.85% | +12.0% | |
| LIFE | Sell | ATYR PHARMA INC | $9,994,804 | -1.4% | 4,627,224 | -4.1% | 3.60% | +6.1% |
| XFOR | New | X4 PHARMACEUTICALS, INC. | $8,934,210 | – | 4,605,263 | +100.0% | 3.22% | – |
| SCYX | Buy | SCYNEXIS INC | $8,691,721 | +543.8% | 2,946,346 | +554.7% | 3.14% | +592.1% |
| XOMA | Buy | XOMA CORP | $6,600,147 | -1.7% | 349,399 | +9.8% | 2.38% | +5.7% |
| RZLT | Sell | REZOLUTE INC | $6,083,502 | +2.6% | 3,072,476 | -0.5% | 2.19% | +10.4% |
| TELA | New | TELA BIO INC | $4,888,930 | – | 482,619 | +100.0% | 1.76% | – |
| URGN | Sell | UROGEN PHARMA LTD | $4,642,058 | -28.4% | 448,508 | -36.1% | 1.67% | -23.0% |
| XGN | Buy | EXAGEN INC | $3,043,121 | +20.8% | 1,049,352 | +1.2% | 1.10% | +29.9% |
| GMDA | New | GAMIDA CELL LTD | $2,895,000 | – | 1,500,000 | +100.0% | 1.04% | – |
| AVIR | Buy | ATEA PHARMACEUTICALS INC | $2,812,809 | +22.7% | 752,088 | +9.9% | 1.02% | +32.0% |
| DCTH | New | DELCATH SYSTEMS, INC. | $2,097,912 | – | 378,787 | +100.0% | 0.76% | – |
| CSTL | Sell | CASTLE BIOSCIENCES INC | $1,261,938 | -81.0% | 91,978 | -68.6% | 0.46% | -79.6% |
| New | AYTU BIOPHARMA INC | $755,790 | – | 472,369 | +100.0% | 0.27% | – | |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -1,000 | -100.0% | 0.00% | – |
| Exit | CONFORMIS INC | $0 | – | -402,651 | -100.0% | -0.22% | – | |
| TVTX | Exit | TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $0 | – | -132,005 | -100.0% | -1.00% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -370,000 | -100.0% | -1.23% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -416,519 | -100.0% | -1.37% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -6,535,674 | -100.0% | -9.21% | – |
| AMYT | Exit | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $0 | – | -6,278,085 | -100.0% | -30.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.